Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 26 Hodgkin Disease 23 Lymphoma 8 Sarcoma 5 Uveal Melanoma 4 Neoplasm Metastasis 4 Neoplasms 2 Leiomyosarcoma 2 Solitary Fibrous Tumors 1 Solid Tumor 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Immunotherapy 1 Hyperthermia 1 HIV Infections 1 Carcinoma 1 Advanced Melanoma 1 Acquired Immunodeficiency Syndrome 1 AIDS-Related Complex 1

Interventions

apatinib 3 vistusertib 2 olaparib 2 camrelizumab 2 atezolizumab 2 Ipilimumab 2 Everolimus 2 trametinib 1 tilsotolimod 1 tazemetostat 1 tazarotene 1 spartalizumab 1 sargramostim 1 sacituzumab govitecan 1 rucaparib 1 roniciclib 1 romiplostim 1 pyrotinib 1 phosphorylethanolamine 1 pemigatinib 1 pembrolizumab 1 pazopanib 1 palbociclib 1 niraparib 1 magrolimab 1 lenvatinib 1 irinotecan sucrosofate 1 famitinib 1 dalpiciclib 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡